Core Viewpoint - Tianjin Development (00882.HK) announced a partnership agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical, with several investment entities to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1 - The fund will primarily invest in equity of unlisted companies and publicly traded stocks issued or traded in a non-public manner, focusing on the health and biotechnology sectors in China [1] - Lifesun Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund, subject to the terms and conditions of the partnership agreement [1] - The investment areas include innovative drugs, medical devices, in vitro diagnostic devices (IVD), medical services, "CXO" and related pharmaceutical outsourcing services, pharmaceutical-related equipment or consumables, life science instruments and tools, medical technology (including medical big data, AI life sciences, internet healthcare), synthetic biology, bio-agriculture, biomass energy, brain science, medical consumer products, elderly care, traditional Chinese medicine, cell and gene therapy, and other high-quality projects recognized by the investment decision committee [1]
天津发展(00882.HK)出资1.74亿参与设立基金 投资中国大健康及生物技术领域